Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Negev Capital is a venture capital firm founded to address the escalating mental health crisis through investments in psychedelic medicine. Established in the United States, the firm focuses on early-stage clinical development of psychedelic therapies aimed at treating neurological and psychiatric disorders. The fund has a total size of $30 million and actively seeks to support companies that are pioneering advancements in this field.
Currently, Negev Capital manages assets totaling $30 million and has invested in three notable portfolio companies. The firm operates primarily in the United States, Canada, and Israel, with a mission to tackle significant unmet medical needs in mental health through innovative solutions. Negev Capital has established itself as a key player in the psychedelic medicine sector, emphasizing the importance of early-stage clinical research and development.
Negev Capital primarily invests in companies that are developing medications in the preclinical or Phase I clinical stages. The firm targets investments ranging from $500,000 to $2 million, focusing on sectors such as healthcare and biotech, specifically within the realm of psychedelic medicine. The geographic focus includes the United States, Canada, the European Union, and Israel, allowing for a broad reach in identifying promising startups.
The firm’s investment thesis centers on addressing the mental health crisis through the development of psychedelic treatments. Negev Capital seeks to partner with companies that are innovating in the field of psychedelic therapies, particularly those that show potential for significant impact on neurological and psychiatric disorders. The firm emphasizes the importance of addressing unmet medical needs and aims to support the clinical development of these groundbreaking therapies.
Negev Capital's portfolio includes three notable companies that are at the forefront of psychedelic medicine:
Cosmo Feilding Mellen: Director and CEO of Beckley Psytech, Cosmo has extensive experience in the psychedelic medicine sector and has led various initiatives aimed at integrating these therapies into modern healthcare.
James Lanthier: CEO of Mindset Pharma, James has a strong background in drug development and has been instrumental in advancing the company's innovative psychedelic compounds.
Damian Kettlewell: CEO, Co-Founder & Director of Filament Health, Damian brings expertise in natural product development and has a focus on creating safe, standardized psychedelic medicines.
Ben Lightburn: CEO and Co-Founder of Filament Health, Ben has a background in biotechnology and is dedicated to advancing the field of psychedelic medicine through rigorous research and development.
To pitch Negev Capital, founders should visit the firm's website at negevcap.com. The pitch deck should include comprehensive information about the startup's product, market potential, and clinical development plans. Negev Capital appreciates clarity and detail in presentations.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory.
As of March 2023, Negev Capital continues to actively invest in the psychedelic medicine sector, focusing on early-stage companies. The firm has made significant strides in supporting its portfolio companies, including Mindset Pharma Inc., Beckley Psytech, and Filament Health, which are engaged in developing innovative treatments for neurological and psychiatric disorders.
Negev Capital's commitment to addressing the mental health crisis through strategic investments in psychedelic therapies positions it as a key player in the evolving landscape of mental health solutions.
What are Negev Capital's investment criteria?
Negev Capital invests in companies developing psychedelic therapies that are in preclinical or Phase I clinical stages. The firm focuses on addressing significant unmet medical needs in mental health.
How can I apply or pitch to Negev Capital?
Founders can submit their pitches through Negev Capital's website at negevcap.com. It is advisable to include detailed information about the company's stage, product, and market potential.
What makes Negev Capital different from other investors?
Negev Capital specializes in psychedelic medicine, focusing on early-stage clinical development. The firm aims to address the mental health crisis through strategic investments in innovative therapies.
What is the geographic scope of Negev Capital's investments?
The firm primarily invests in the United States, Canada, the European Union, and Israel, allowing for a diverse range of opportunities in the psychedelic medicine sector.
What is the typical fund size and check size for Negev Capital?
Negev Capital has a fund size of $30 million, with average investments ranging from $500,000 to $2 million per deal.
What kind of post-investment involvement does Negev Capital have?
Negev Capital provides strategic guidance and resources to its portfolio companies, facilitating the development of innovative psychedelic treatments that address critical mental health challenges.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.